- Home
- ARCT vs CYPH Comparison
ARCT vs CYPH Comparison
Compare ARCT & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$6.26
N/A
Current Price
$1.20
Company Overview
Basic Information| Metric | ARCT | CYPH |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.1M | 155.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ARCT | CYPH |
|---|---|---|
| Price | $6.26 | $1.20 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $38.67 | N/A |
| AVG Volume (30 Days) | 706.5K | ★ 6.7M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $97,601,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.85 | $0.22 |
| 52 Week High | $24.17 | $3.70 |
Technical Indicators
Market Signals| Indicator | ARCT | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 34.10 | N/A |
| Support Level | $6.34 | N/A |
| Resistance Level | $6.75 | N/A |
| Average True Range (ATR) | 0.39 | 0.00 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 2.30 | 0.00 |
Price Performance
Historical Comparison ARCT
CYPH
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.